The present invention relates to a method for stratifying a patient into a clinically relevant group comprising the identification of the probability of an alteration within one or more sets of molecular data from a patient sample in comparison to a
database of molecular data of known phenotypes, the
inference of the activity of a
biological network on the basis of the probabilities, the identification of a
network information flow probability for the patient via the probability of interactions in the network, the creation of multiple instances of
network information flow for the patient sample and the calculation of the distance of the patient from other subjects in a
patient database using multiple instances of the
network information flow. The invention further relates to a biomedical marker or group of biomedical markers associated with a
high likelihood of responsiveness of a subject to a
cancer therapy wherein the biomedical marker or group of biomedical markers comprises altered
biological pathway markers, as well as to an
assay for detecting, diagnosing, graduating, monitoring or prognosticating a medical condition, or for detecting, diagnosing, monitoring or prognosticating the responsiveness of a subject to a therapy against said medical condition, in particular
ovarian cancer. Furthermore, a corresponding
clinical decision support system is provided.